Low D-serine levels in schizophrenia: A systematic review and meta-analysis

Neuroscience Letters

Volumn 634, Issue , 2016, Pages 42-51

  Cho, Seo Eun ^a   Na, Kyoung Sae ^a   Cho, Seong Jin ^a   Kang, Seung Gul ^a  

^a Gachon University   (South Korea)

Author keywords

D Serine; Meta analysis; N Methyl D aspartate receptor; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BLONANSERIN; BROMPERIDOL; CHLORPROMAZINE; CLOCAPRAMINE; CLOSPIPRAMINE; CLOZAPINE; DEXTRO SERINE; FLUPHENAZINE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; SULTOPRIDE; TRIFLUOPERAZINE; ZIPRASIDONE; SERINE;

ARTICLE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; GENDER; HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SYSTEMATIC REVIEW; BLOOD; CASE CONTROL STUDY; CHEMISTRY; META ANALYSIS; STEREOISOMERISM;

ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; HUMANS; SCHIZOPHRENIA; SERINE; STEREOISOMERISM;

EID: 84990876716     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.10.006     Document Type: Article

References (40)

1. [1] Balu, D.T., Coyle, J.T., The NMDA receptor ‘glycine modulatory site' in schizophrenia: d-serine, glycine, and beyond. Curr. Opin. Pharmacol. 20 (2015), 109–115.
2. [2] Bendikov, I., Nadri, C., Amar, S., Panizzutti, R., De Miranda, J., Wolosker, H., Agam, G., A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr. Res. 90 (2007), 41–51.
3. [3] Brouwer, A., Luykx, J.J., van Boxmeer, L., Bakker, S.C., Kahn, R.S., NMDA-receptor coagonists in serum, plasma, and cerebrospinal fluid of schizophrenia patients: a meta-analysis of case-control studies. Neurosci. Biobehav. Rev. 37 (2013), 1587–1596.
4. [4] Calcia, M.A., Madeira, C., Alheira, F.V., Silva, T.C., Tannos, F.M., Vargas-Lopes, C., Goldenstein, N., Brasil, M.A., Ferreira, S.T., Panizzutti, R., Plasma levels of D-serine in Brazilian individuals with schizophrenia. Schizophr. Res. 142 (2012), 83–87.
5. [5] Chang, H.J., Lane, H.Y., Tsai, G.E., NMDA pathology and treatment of schizophrenia. Curr. Pharm. Des. 20 (2014), 5118–5126.
6. [6] D'Souza, D.C., Radhakrishnan, R., Perry, E., Bhakta, S., Singh, N.M., Yadav, R., Abi-Saab, D., Pittman, B., Chaturvedi, S.K., Sharma, M.P., Bell, M., Andrade, C., Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology 38 (2013), 492–503.
7. [7] Fuchs, S.A., De Barse, M.M., Scheepers, F.E., Cahn, W., Dorland, L., de Sain-van der Velden, M.G., Klomp, L.W., Berger, R., Kahn, R.S., de Koning, T.J., Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients. Eur. Neuropsychopharmacol. 18 (2008), 333–338.
8. [8] Fukushima, T., Iizuka, H., Yokota, A., Suzuki, T., Ohno, C., Kono, Y., Nishikiori, M., Seki, A., Ichiba, H., Watanabe, Y., Hongo, S., Utsunomiya, M., Nakatani, M., Sadamoto, K., Yoshio, T., Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One, 9, 2014, e101652.
9. [9] Hashimoto, A., Oka, T., Nishikawa, T., Anatomical distribution and postnatal changes in endogenous free D-aspartate and D-serine in rat brain and periphery. Eur. J. Neurosci. 7 (1995), 1657–1663.
10. [10] Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindstrom, L.H., Iyo, M., Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 (2005), 767–769.
11. [11] Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., Nakazato, M., Kumakiri, C., Okada, S., Hasegawa, H., Imai, K., Iyo, M., Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 60 (2003), 572–576.
12. [12] Heresco-Levy, U., Durrant, A.R., Ermilov, M., Javitt, D.C., Miya, K., Mori, H., Clinical and electrophysiological effects of D-serine in a schizophrenia patient positive for anti-N-methyl-D-aspartate receptor antibodies. Biol. Psychiatry 77 (2015), e27–29.
13. [13] Hons, J., Vasatova, M., Cermakova, E., Doubek, P., Libiger, J., Different serine and glycine metabolism in patients with schizophrenia receiving clozapine. J. Psychiatr. Res. 46 (2012), 811–818.
14. [14] Hu, W., MacDonald, M.L., Elswick, D.E., Sweet, R.A., The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann. N. Y. Acad. Sci. 1338 (2015), 38–57.
15. [15] Javitt, D.C., Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry 9 (1987), 12–35.
16. [16] Kantrowitz, J.T., Woods, S.W., Petkova, E., Cornblatt, B., Corcoran, C.M., Chen, H., Silipo, G., Javitt, D.C., D-Serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry 2 (2015), 403–412.
17. [17] Kartvelishvily, E., Shleper, M., Balan, L., Dumin, E., Wolosker, H., Neuron-derived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors. J. Biol. Chem. 281 (2006), 14151–14162.
18. [18] Konno, R., Yasumura, Y., D-Amino-acid oxidase and its physiological function. Int. J. Biochem. 24 (1992), 519–524.
19. [19] Konno, R., Yasumura, Y., Mouse mutant deficient in D-amino acid oxidase activity. Genetics 103 (1983), 277–285.
20. [20] Kumashiro, S., Hashimoto, A., Nishikawa, T., Free D-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases. Brain Res. 681 (1995), 117–125.
21. [21] Lane, H.Y., Chang, Y.C., Liu, Y.C., Chiu, C.C., Tsai, G.E., Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized double-blind, placebo-controlled study. Arch. Gen. Psychiatry 62 (2005), 1196–1204.
22. [22] Lane, H.Y., Lin, C.H., Huang, Y.J., Liao, C.H., Chang, Y.C., Tsai, G.E., A randomized double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 13 (2010), 451–460.
23. [23] Liu, R., Dang, W., Du, Y., Zhou, Q., Liu, Z., Jiao, K., Correlation of functional GRIN2A gene promoter polymorphisms with schizophrenia and serum D-serine levels. Gene 568 (2015), 25–30.
24. [24] Madeira, C., Freitas, M.E., Vargas-Lopes, C., Wolosker, H., Panizzutti, R., Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr. Res. 101 (2008), 76–83.
25. [25] Marek, G.J., Behl, B., Bespalov, A.Y., Gross, G., Lee, Y., Schoemaker, H., Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?. Mol. Pharmacol. 77 (2010), 317–326.
26. [26] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151 (2009), 264–269 W264.
27. [27] Mothet, J.P., Le Bail, M., Billard, J.M., Time and space profiling of NMDA receptor co-agonist functions. J. Neurochem. 135 (2015), 210–225.
28. [28] Mothet, J.P., Parent, A.T., Wolosker, H., Brady, R.O. Jr., Linden, D.J., Ferris, C.D., Rogawski, M.A., Snyder, S.H., D-Serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 4926–4931.
29. [29] Ohnuma, T., Sakai, Y., Maeshima, H., Hatano, T., Hanzawa, R., Abe, S., Kida, S., Shibata, N., Suzuki, T., Arai, H., Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008), 1905–1912.
30. [30] Ozeki, Y., Sekine, M., Fujii, K., Watanabe, T., Okayasu, H., Takano, Y., Shinozaki, T., Aoki, A., Akiyama, K., Homma, H., Shimoda, K., Phosphoserine phosphatase activity is elevated and correlates negatively with plasma d-serine concentration in patients with schizophrenia. Psychiatry Res. 237 (2016), 344–350.
31. [31] Papouin, T., Ladepeche, L., Ruel, J., Sacchi, S., Labasque, M., Hanini, M., Groc, L., Pollegioni, L., Mothet, J.P., Oliet, S.H., Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150 (2012), 633–646.
32. [32] Sacchi, S., Rosini, E., Pollegioni, L., Molla, G., D-Amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Curr. Pharm. Des. 19 (2013), 2499–2511.
33. [33] Schell, M.J., Molliver, M.E., Snyder, S.H., D-Serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 3948–3952.
34. [34] Singh, S.P., Singh, V., Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 25 (2011), 859–885.
35. [35] Tsai, G., Yang, P., Chung, L.C., Lange, N., Coyle, J.T., D-Serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 44 (1998), 1081–1089.
36. [36] Tsai, G.E., Yang, P., Chung, L.C., Tsai, I.C., Tsai, C.W., Coyle, J.T., D-Serine added to clozapine for the treatment of schizophrenia. Am. J. Psychiatry 156 (1999), 1822–1825.
37. [37] Weiser, M., Heresco-Levy, U., Davidson, M., Javitt, D.C., Werbeloff, N., Gershon, A.A., Abramovich, Y., Amital, D., Doron, A., Konas, S., Levkovitz, Y., Liba, D., Teitelbaum, A., Mashiach, M., Zimmerman, Y., A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J. Clin. Psychiatry 73 (2012), e728–734.
38. [38] Yamada, K., Ohnishi, T., Hashimoto, K., Ohba, H., Iwayama-Shigeno, Y., Toyoshima, M., Okuno, A., Takao, H., Toyota, T., Minabe, Y., Nakamura, K., Shimizu, E., Itokawa, M., Mori, N., Iyo, M., Yoshikawa, T., Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Biol. Psychiatry 57 (2005), 1493–1503.
39. [39] Yamamori, H., Hashimoto, R., Fujita, Y., Numata, S., Yasuda, Y., Fujimoto, M., Ohi, K., Umeda-Yano, S., Ito, A., Ohmori, T., Hashimoto, K., Takeda, M., Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neurosci. Lett. 582 (2014), 93–98.
40. [40] Yang, Y., Ge, W., Chen, Y., Zhang, Z., Shen, W., Wu, C., Poo, M., Duan, S., Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 15194–15199.